Saves everyone looking it up:
Further details on the Phase IIb trial design including the expected timing for trial application and approval for the Phase IIb trial of ATL1102 in non-ambulant DMD patients to be conducted in Europewill be communicated to the market once the final opinion is received from PDCO following their 15 October 2021 meeting.
- Forums
- ASX - By Stock
- Ann: Positive feedback received on Paediatric Investigation Plan
Saves everyone looking it up: Further details on the Phase IIb...
- There are more pages in this discussion • 124 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.9¢ |
Change
0.005(7.81%) |
Mkt cap ! $64.01M |
Open | High | Low | Value | Volume |
6.6¢ | 7.1¢ | 6.5¢ | $75.51K | 1.104M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3077 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 4995 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3077 | 0.069 |
1 | 200000 | 0.068 |
1 | 156250 | 0.067 |
2 | 40060 | 0.066 |
3 | 516040 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 4995 | 1 |
0.074 | 114944 | 1 |
0.075 | 100000 | 1 |
0.076 | 143169 | 1 |
0.077 | 160000 | 1 |
Last trade - 12.32pm 26/04/2024 (20 minute delay) ? |
|
|||||
Last
6.9¢ |
  |
Change
0.005 ( 16.0 %) |
|||
Open | High | Low | Volume | ||
6.6¢ | 7.1¢ | 6.6¢ | 228866 | ||
Last updated 12.18pm 26/04/2024 ? |
Featured News
PER (ASX) Chart |